Key Takeaways
- The Indian government plans to invest ₹10,000 crore in biotechnology, aiming to establish the country as a biopharma manufacturing hub.
- New educational programs in biotechnology are being developed to adapt to the evolving demands of personalized medicine.
- Technological advancements like AI are enhancing drug discovery and tailoring healthcare solutions for individuals.
Investment Boost for Biotechnology Sector
The Indian government has announced a substantial investment of ₹10,000 crore for the biotechnology sector in the Union Budget 2026-27. This initiative aims to position India as a global hub for biopharmaceutical manufacturing, emphasizing the production of biologics and biosimilars through the Biopharma Shakti initiative.
During a recent webinar titled “Biotech Education in Personalised Medicine,” industry experts expressed optimism about the future of biotechnology. Meenakshi Sinha, director at Cipla, noted the profession’s stability and growth potential, as healthcare demand continues to rise alongside strong government support. This investment creates ample career opportunities for students entering the biotechnology field.
The webinar was co-hosted by the Vellore Institute of Technology (VIT), Chennai, and The Hindu. It is part of a series exploring biotechnology’s transformative influence across various sectors, including healthcare, agriculture, and environmental solutions. S. Shridevi, a professor at VIT, discussed the impact of advanced technologies like AI and machine learning on drug discovery, noting a critical shift toward personalized medicine based on individual genetic and lifestyle factors.
In line with these developments, VIT announced a new biotechnology program scheduled for 2027. G. Jayaraman, Professor and Dean of the School of Bio Sciences & Technology at VIT, emphasized the importance of bioinformatics and computational biology in preparing students for future industries. The program will focus on innovative strategies to ensure graduates meet the evolving demands of the biopharma sector.
Parul Ganju, co-founder and CEO of Ahammune Biosciences, pointed out that the COVID-19 pandemic significantly transformed the biotechnology landscape, leading to rapid advancements in vaccines and therapeutics that have saved countless lives. The panelists highlighted the growing role of biotechnology in creating tailored healthcare solutions, particularly in managing complex diseases such as cancer and autoimmune disorders.
As the field of biotechnology matures, it is expected to drive further advancements in personalized medicine. This evolution will enable more precise diagnoses and targeted therapies, enhancing the effectiveness and efficiency of treatment approaches.
For those interested in exploring these topics further, a recording of the webinar is available online.
The content above is a summary. For more details, see the source article.